RAM - IGAN PARTNERSHIP ADVANCES COMMERCIALISATION OF THE WHOLE-BODY MONITORING QUANTUM SENSOR, OPERATING 70% FASTER THAN AIOCT 27, 2019 @4.25AM
(Extreme right) Ayal Ram, CEO of RAM Group demonstrating QDS' advanced capabilities in generating comprehensive cardio-pulmonary diagnosis
from a Single-Point Monitoring chip as Raj Kumar, Group
CEO, IGSS Ventures (centre background) watches.
The Quantum Device Sensor enables full-body monitoring capabilities through a "Single-Point Monitoring chip" powered by Artificial General
Intelligence
Singapore based technology providers RAM Group in multiparametric, single-point bio-electro-mechanical quantum sensor technology and IGSS GAN Pte Ltd (IGaN) fabrication experts in 8” gallium nitride on silicon (GaN-on-Si) have announced the world’s first clinically-validated Quantum Device Sensor (QDS) providing non-invasive, continuous whole-body organ system monitoring.
Billed as one of the most advanced sensors of its kind for an array of healthcare applications and wearables, QDS integrates proprietary Artificial General Intelligence (AGI) engine to produce a new level of data sets with the potential to aid immediate and hyper-accurate diagnosis of diseases or disorders in the heart, lungs and other organs. “Traditional sensors are limited to monitoring one parameter at a time which is costly and requires separate tests that are often too invasive, too specific or need frequent recalibration to produce accurate results. And today, none are capable of continuous monitoring of individual organs,” began Ayal Ram, CEO of RAM Group. “Powered by proprietary AGI that operates 70% faster than AI in neural net analysis, the QDS addresses the need for small, ultra-low power, non-invasive sensor that can simultaneously and continuously detect minute changes in electrical fields within the human body. It fundamentally transforms the way critical illnesses and disease states are detected, diagnosed and understood sooner with less stress and cost,” said Ram. Signal-to-noise ratio QDS’ advanced sensing platform utilises GaN-on-Si compound semiconductors alongside a set of proprietary materials to create a sensor that reportedly is over ten thousand times more sensitive in signal-to-noise ratio than anything currently in the market. Leveraging IGaN’s proprietary GaN 8” (200mm) fabrication technologies, QDS taps into existing silicon infrastructure to deliver superior performance that is at least comparable if not at a significantly reduced total cost, allowing global commercialisation at scale. Quantum cardiorespiratory monitor Among the first commercially-ready healthcare application is the quantum Cardiorespiratory Monitor, or qCRM which houses the AGI-powered QDS sensor inside a comfortable wearable device to generate comprehensive cardio-pulmonary diagnosis and analysis including cuff-less blood pressure. This is done by converting signals from QDS’ Single-Point Monitoring (SPM) chip into unified waveforms that represent comprehensive electrical and mechanical functions and processes of the heart and lungs, as well as intestinal motility, and the interrelation of neurology to the cardiopulmonary system. The QDS bio-signal analytics goes beyond current technologies that monitor optical fields or mechanical effects like the photoplethysmography (PPG) sensor found in all wearable smartwatches measuring the indirect mechanical movement of the cardiac-cycle alone. With the ability to not only detect the smallest changes in energy states, it analyses multiple signals in the body and the causal connection between these bio-signals through a single sensor that can do the work of multiple diagnostic devices. QDS enables more robust machine learning through a range and depth of data previously inaccessible, creating an ecosystem to deliver patients the best odds and cost savings from unnecessary procedures, reducing emergency room visits and hospital readmissions. RAM Group is working to advance its potential by expediting clinical trials, allowing new therapies to reach patients faster. The first QDS product is expected to be commercially available in fourth quarter 2020. Its compound semiconductor-based technology facilitates multi-parametric (HR, RAP, LAP, BP, BR) and multi-variant (heart mechanical functions, cardiac-output, circulatory dynamics, cardiac electrophysiology) analysis, and consumes significantly less power. “In our study, the qCRM performed extremely well against a myriad of accepted monitoring technologies which is extraordinary considering qCRM utilises only one point of contact for the sensor to receive this level of organ function data from the patient,” said Dr Ardeshir Ghofrani, 2015 German Future Prize winner and leader of the medical research team at Giessen University Hospital. “Operating and analysing continuously, increasing data safety and removing human errors means that the potential uses for this diagnostic and monitoring technology are significant.” With the ability to measure the smallest interactions in a multitude of mediums, QDS leapfrogs quantum sensing technologies that tap into US$23B multi-sector opportunity in 2020 spanning the broadest of applications ranging from health and wellness, food safety, oil and gas, defence, communications, smart cities and homes and automotive. 
|
Roche launch Perjeta - Herceptin combination, a post surgery treatment for early breast cancer (eBC)
Keytruda with chemotherapy to be the first line of treatment for patients with advanced lung cancer
|
Copyright@ 2018 Healthcare Today. All rights reserved. The material in this site is intended to be of general information use and is not intended to constitute medical
advice, probable diagnosis or recommended treatments.
advice, probable diagnosis or recommended treatments.